Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 85898-101

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 85898-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marp Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

515b3bc6 6c63 6669 E063 6294a90a1a02

515b3bc6 6c63 6669 E063 6294a90a1a02
FDA Label Image

Figure1 (Figure 1)

Figure1 (Figure 1)
This text provides a brief explanation of a mathematical formula or model related to evaluating the number of primary amine groups, cross-linking groups, and indicating an extended polymer network.*
FDA Label Image

Figure2 (Figure 2)

Figure2 (Figure 2)
FDA Label Image

Figure3 (Figure 3)

Figure3 (Figure 3)
This is a data visualization illustrating the percentage of patients achieving a reduction in serum phosphorus levels from baseline. The X-axis represents the reduction in serum phosphorus levels (mg/dL), while the Y-axis shows the percentage of patients attaining a reduction at least as great as the value on the X-axis. The data compares an active control group with sevelamer Hydrochloride. The chart indicates both improvement and worsening in phosphorus levels, providing valuable insights into treatment effectiveness.*
FDA Label Image

Figure4 (Figure 4)

Figure4 (Figure 4)
FDA Label Image

Sevelamer Label Image (Mp Sel 270 Label 1.1)

Sevelamer Label Image (Mp Sel 270 Label 1.1)
This text provides information on a medication named Sevelamer Carbonate in tablet form. Each film-coated tablet contains 800 mg of Sevelamer carbonate along with inactive ingredients such as diacetylated monoglycerides, hypromellose, microcrystalline cellulose, silicon dioxide, and zinc stearate. The usual dosage instructions are not provided in the text, but storage guidelines recommend keeping the tablets at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). It also notes to protect the tablets from moisture, dispense in a tight container, and keep them out of reach of children. The medication is manufactured for MarpPharma based in Boerne, Texas, USA, and is manufactured by Haimen Pharma Inc. located in Jiangsu, China.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
This is a table showing the recommended starting dose for dialysis patients who are switching from calcium acetate to sevelamer carbonate tablets. The table provides information on the number of tablets to be taken per meal for each type of medication.*
FDA Label Image

Table 5 (Table 5)

Table 5 (Table 5)
The provided text includes information about drug interactions with sevelamer. It mentions oral drugs that showed no change in pharmacokinetics when administered with sevelamer, such as Digoxin, Enalapril, Iron, Metoprolol, and Warfarin. Additionally, it lists drugs that have demonstrated interactions with sevelamer, including Ciprofloxacin and Mycophenolate mofetil, indicating specific dosing recommendations to be administered separately from sevelamer carbonate tablets.*
FDA Label Image

Table 6 (Table 6)

Table 6 (Table 6)
This is a table presenting the mean serum Phosphorus levels (in mg/dL) at baseline and endpoint for a group of 81 patients taking Sevelamer Hydrochloride. The table includes data on the values at baseline, end of washout, and endpoint, as well as the change from baseline at the endpoint. Additionally, it shows the 95% confidence interval for the change from baseline at the endpoint. The statistical significance within the treatment group comparison is indicated as p<0.0001.*
FDA Label Image

Table7 (Table 7)

Table7 (Table 7)
This text appears to be a table displaying measurements related to phosphorus levels and the calcium-phosphorus ion product before and after treatment. The baseline values for phosphorus level were 75 and 73, with changes from baseline at 21 and 18 respectively. The baseline values for the calcium-phosphorus ion product were 705 and 684, with changes from baseline at 194 and -142 respectively at endpoint.*
FDA Label Image

Table (Table)

Table (Table)
This is a table outlining the starting dose of sevelamer carbonate for adult dialysis patients who are not taking a phosphate binder. The dose is based on the serum phosphorus level, with different dosages recommended for different ranges of phosphorus levels.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.